These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22555222)

  • 1. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
    Das M; Riess JW; Frankel P; Schwartz E; Bennis R; Hsieh HB; Liu X; Ly JC; Zhou L; Nieva JJ; Wakelee HA; Bruce RH
    Lung Cancer; 2012 Aug; 77(2):421-6. PubMed ID: 22555222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
    Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
    J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF; Deng SJ; Weng WW; Guo G; Chen N
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Friboulet L; Barrios-Gonzales D; Commo F; Olaussen KA; Vagner S; Adam J; Goubar A; Dorvault N; Lazar V; Job B; Besse B; Validire P; Girard P; Lacroix L; Hasmats J; Dufour F; André F; Soria JC
    Clin Cancer Res; 2011 Sep; 17(17):5562-72. PubMed ID: 21750204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
    Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer].
    Ma W; Li W; Gao M; Li XN
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):371-4. PubMed ID: 21875468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
    Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.